NDLI: Alendronate adherence and its impact on hip-fracture risk in patients with established osteoporosis in Taiwan.

Please wait, while we are loading the content...

Year: 2017 Volume: 101

Year: 2016 Volume: 100

Year: 2016 Volume: 99

Year: 2015 Volume: 98

Year: 2015 Volume: 97

Year: 2014 Volume: 96

Year: 2014 Volume: 95

Year: 2013 Volume: 94

Year: 2013 Volume: 93

Year: 2012 Volume: 92

Year: 2012 Volume: 91

Year: 2011 Volume: 90

Year: 2011 Volume: 90 Issue: 6

Year: 2011 Volume: 90 Issue: 5

Year: 2011 Volume: 90 Issue: 4

Year: 2011 Volume: 90 Issue: 3

Year: 2011 Volume: 90 Issue: 2

Year: 2011 Volume: 90 Issue: 1

Alendronate adherence and its impact on hip-fracture risk in patients with established osteoporosis in Taiwan.

A randomized study of the efficacy and safety of intravenous acetaminophen vs. intravenous placebo for the treatment of fever.

Genetically polymorphic OCT1: another piece in the puzzle of the variable pharmacokinetics and pharmacodynamics of the opioidergic drug tramadol.

Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimal and noninvasive probes for hepatic and first-pass CYP3A induction.

The human placental perfusion model: a systematic review and development of a model to predict in vivo transfer of therapeutic drugs.

Impact of smoking, smoking cessation, and genetic polymorphisms on CYP1A2 activity and inducibility.

Predicting adverse drug reactions using publicly available PubChem BioAssay data.

Detecting drug interactions from adverse-event reports: interaction between paroxetine and pravastatin increases blood glucose levels.

Pharmacokinetic impact of SLCO1A2 polymorphisms on imatinib disposition in patients with chronic myeloid leukemia.

Cigarette smoking, nicotine, and body weight.

The male genital tract is not a pharmacological sanctuary from efavirenz.

Implications of obesity for drug therapy: limitations and challenges.

Population pharmacokinetic-pharmacodynamic analysis of trastuzumab-associated cardiotoxicity.

Biomarkers for the prediction of type 2 diabetes and cardiovascular disease.

New drug targets for the treatment of obesity.

Obesity and the 'obesity paradox' in cardiovascular diseases.

Practical ethics: establishing a pathway to benefit for complex pharmacogenomic tests.

The importance of high-quality evidence of the long-term impact of nonfatal events used in randomized controlled trials: a case study of prasugrel.

Regulatory science as a bridge between science and society.

Year: 2011 Volume: 89

Year: 2010 Volume: 88

Year: 2010 Volume: 87

Year: 2009 Volume: 86

Year: 2009 Volume: 85

Year: 2008 Volume: 84

Year: 2008 Volume: 83

Year: 2007 Volume: 82

Year: 2007 Volume: 81

Year: 2005 Volume: 77

Year: 2004 Volume: 75

Year: 1998 Volume: 63

Year: 1993 Volume: 54

Year: 1992 Volume: 51

Year: 1989 Volume: 46

Year: 1986 Volume: 39

Alendronate adherence and its impact on hip-fracture risk in patients with established osteoporosis in Taiwan.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Lin, T-C Yang, C-Y Yang, Y-H Kao Lin, S-J
Spatial Coverage	Taiwan
Description	Country affiliation: Taiwan Author Affiliation: Lin TC ( Institute of Biopharmaceutical Science, College of Medicine, National Cheng Kung University, Tainan, Taiwan.)
Abstract	A pharmacoepidemiology study was conducted using the health insurance database in Taiwan to assess compliance with osteoporosis drug regimens and the impact of compliance on the risk for secondary fractures. Patients >50 years of age with vertebral/hip fracture who had been started on alendronate therapy for the first time only after the fracture were included. Compliance was measured using the medication possession ratio (MPR) and was included as a time-dependent covariate in the Cox model to compare the difference between compliant (MPR ≥ 80%) and noncompliant patients (MPR <80%) with respect to risk for subsequent hip fractures. Only 38% of the study population remained compliant during the first year of treatment. Over the 4-year follow-up period, the risk of hip fracture among the compliant patients was 70% lower than that among the noncompliant ones (adjusted hazard ratio (HR) 0.30). Among patients with osteoporosis in Taiwan who had experienced a fracture and had started alendronate therapy, compliance with the dosage regimen was suboptimal. It was also found that compliance significantly reduced the risk of secondary hip fracture up to 4 years.
File Format	HTM / HTML
ISSN	00099236
Issue Number	1
Volume Number	90
e-ISSN	15326535
Journal	Clinical Pharmacology & Therapeutics
Language	English
Publisher	Wiley
Publisher Date	2011-07-01
Publisher Place	United States
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Pharmacology Alendronate Therapeutic Use Bone Density Conservation Agents Hip Fractures Epidemiology Osteoporosis Complications Prevention & Control Aged Analysis Of Variance Asian Continental Ancestry Group Cohort Studies Comorbidity Data Mining Databases, Factual Female Humans Male Middle Aged Osteoporosis, Postmenopausal Drug Therapy Patient Compliance Regression Analysis Retrospective Studies Risk Risk Factors Spinal Fractures Taiwan Journal Article Research Support, Non-u.s. Gov't
Content Type	Text
Resource Type	Article
Subject	Pharmacology Pharmacology (medical)

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Low incidence of anti-osteoporosis treatment after hip fracture.

Association of the presence of bone bars on radiographs and hip fracture in postmenopausal Caucasian women.

Hip structure analysis of bisphosphonate-treated Japanese postmenopausal women with osteoporosis.

Estrogen receptor alpha gene PvuII polymorphism and risk of fracture in postmenopausal women: a meta-analysis.

Residual lifetime and 10 year absolute risks of osteoporotic fractures in Chinese men and women.

Consistency of fracture risk reduction in Japanese and Caucasian osteoporosis patients treated with teriparatide: a meta-analysis.

Relationship between compliance and persistence with osteoporosis medications and fracture risk in primary health care in France: a retrospective case-control analysis.

Medical specialty-related adherence to anti-osteoporotic regimens in fragility hip fracture patients.

Economic Evaluation of Oral Alendronate Therapy for Osteoporosis in Chinese Postmenopausal Women: The Impact of Medication Compliance and Persistence

Alendronate adherence and its impact on hip-fracture risk in patients with established osteoporosis in Taiwan.

Similar Documents

Low incidence of anti-osteoporosis treatment after hip fracture.

Association of the presence of bone bars on radiographs and hip fracture in postmenopausal Caucasian women.

Hip structure analysis of bisphosphonate-treated Japanese postmenopausal women with osteoporosis.

Estrogen receptor alpha gene PvuII polymorphism and risk of fracture in postmenopausal women: a meta-analysis.

Residual lifetime and 10 year absolute risks of osteoporotic fractures in Chinese men and women.

Consistency of fracture risk reduction in Japanese and Caucasian osteoporosis patients treated with teriparatide: a meta-analysis.

Relationship between compliance and persistence with osteoporosis medications and fracture risk in primary health care in France: a retrospective case-control analysis.

Medical specialty-related adherence to anti-osteoporotic regimens in fragility hip fracture patients.

Economic Evaluation of Oral Alendronate Therapy for Osteoporosis in Chinese Postmenopausal Women: The Impact of Medication Compliance and Persistence

Alendronate adherence and its impact on hip-fracture risk in patients with established osteoporosis in Taiwan.